Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrine Tumors
•
Endocrinology
Does octreotide therapy interfere with the ability to localize an insulinoma via radionuclide diagnostic studies?
Related Questions
Is tall cell variant papillary thyroid cancer automatically categorized as intermediate risk regardless of other histopathological features and should consequently be treated with RAI?
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long-term CVD risk?
How long after a successful parathyroid surgery would you reassess bone density in a patient with severe osteoporosis ?
What doses of methimazole do you consider "low dose" when treating Graves' disease long-term?
What is your preferred next therapeutic step in managing a patient with type 2 diabetes on a GLP-1 RA with a hemoglobin A1c of 8.9%?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
At what age and how often do you screen for osteoporosis in non-ambulatory (e.g. developmentally disabled) young adults without other risk factors?
Would you consider changing a non-diabetic patient with obesity and a history of CAD who is on semaglutide to tirzepatide if they have not achieved their weight loss goals?
Is it safe to use acarbose in patients with advanced chronic kidney disease?
For patients with Hashimoto's thyroiditis, is there a commercially available blood test for detecting abnormalities in the type 1 deiodinase enzyme in order to identify patients who would potentially benefit from T4 and T3 combination therapy?
